Clostridium Vaccine MarketSize and Trends

Growing C. difficile infections at healthcare facilities and antibiotic resistance to treatment drugs are propelling demand for development of prophylactic options to reduce the risk of infection in vulnerable patients. A 2013 bulletin published from the Centers for Disease Control and Prevention (CDC) outlined Clostridium difficile as urgent antibiotic-resistance threats in the U.S.

Currently, there is no alternative therapies apart from antibiotics available for the treatment of clostridium difficile infection and only option available is surgery (in severe cases), fecal microbiota transplant, and probiotics in case of recurrent clostridium difficile infection.

Moreover, key pharmaceutical players are engaged in conducting clinical trials for development of clostridium vaccine that can offer preventive measure in the clostridium difficile infection in near future.

For instance, in January 2017; Pfizer announced phase II study of investigational clostridium difficile vaccine candidate: PF-06425090; for the prevention of C. difficile infection. This randomized phase II study was conducted to examine the safety, tolerability, and immunogenicity of the vaccine in healthy adults 65 to 85 years of age. Pfizer initiated a phase III study in March 2017, with around 16,000 participants.

In July 2016, Valneva SE announced the successful completion of its phase II clinical study for its prophylactic vaccine candidate VLA84 targeting on primary prevention of C. difficile infection (CDI).

Clostridium Vaccine Market Drivers

Rising incidence and high prevalence of clostridium difficile infection is expected to boost growth of the market over the forecast period. Incidence of clostridium difficile infection has been witnessing an increase since the recent past, due to its infection recurrence and antibiotic resistance. According to Centers for Disease Control and Prevention (CDC), in 2015 around half a million people in the U.S. suffer from clostridium difficile infection in a year.

Moreover, according to National Center for Biotechnology Information (NCBI), an estimated 37,900 patients were suffering from clostridium difficile infection in Canada in 2012. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016, reported significant incidence of clostridium difficile infection in China.

Market Trends

Growing clostridium infections in healthcare facilities and antibiotic resistance to treatment drugs drive demand for vaccine development. According to CDC, clostridium infections were considered urgent antibiotic-resistance threats in 2013, highlighting the need for preventive vaccines. Pfizer's ongoing Phase III study for its PF-06425090 vaccine, and Valneva SE's successful completion of Phase II for VLA84, push the development of clostridium vaccines to address these challenges.

Market Trends

Market trends highlight the urgent need for vaccines to combat clostridium infections, especially in regions like North America where infection rates are climbing. Clinical trials by major players like Pfizer and Valneva SE signify the industry's proactive approach to meet this demand.

Forecast Period

The market is expected to show significant growth during the next forecast period, driven by rising clostridium infection rates and antibiotic resistance. The forecast period focuses on the next decade as companies like Pfizer and Valneva SE develop and potentially commercialize their vaccine candidates, PF-06425090 and VLA84 respectively, pending successful trial outcomes.